SavedAdd your journal

Journals / Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi / 2019 / Cilt: 14 - Sayı: 3

Hypertension and Erectile Dysfunction

Hipertansiyon ve Erektil Disfonksiyon

Orçun ALTUNÖREN
Ertuğrul ERKEN
Özkan GÜNGÖR
Yasemin Coşkun YAVUZ
Pages
162–166
Publication Date
2019-11-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Phosphodiesterase 5 inhibitors can be used safely in treatment of erectile dysfunction in hypertensive patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Erectile dysfunction is a common problem which is seen among hypertensive patients.
📊
Key Findings & Data:It is thought that medications used in treatment of hypertension may contribute this problem as well.
💡
Conclusion & Impact:Phosphodiesterase 5 inhibitors can be used safely in treatment of erectile dysfunction in hypertensive patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Erektil disfonksiyon · Fosfodiesteraz 5 inhibitörü · Hipertansiyon

Abstract

Erectile dysfunction is a common problem which is seen among hypertensive patients. It is thought that medications used in treatment of hypertension may contribute this problem as well. Contrary to common belief, new generation drugs doesn’t produce adverse effect on erectile function. Phosphodiesterase 5 inhibitors can be used safely in treatment of erectile dysfunction in hypertensive patients.

Özet

Erektil disfonksiyon hipertansif hastalarda sık görülen bir problemdir. Hipertansiyonun kendisi kadar tedavide kullanılan ilaçların da bu probleme katkıda bulunabileceği düşünülmektedir Ancak yaygın inanışın aksine özellikle yeni nesil antihipertansif ilaçlar erektil fonksiyon üzerine olumsuz etkilerde bulunmamaktadır. Hipertansif hastalarda erektil disfonksiyon tedavisinde fosfodiesteraz 5 inhibitörleri güvenle kullanılabilmektedir.

🔖

Cite This Article

ALTUNÖREN, O., ERKEN, E., GÜNGÖR, Ö., YAVUZ, Y. C. (2019). Hypertension and Erectile Dysfunction. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, Cilt: 14 - Sayı: 3, 162–166. https://ajindex.com/articles/783334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: Results from the Health Professionals Follow-Up Study. Ann Intern Med 2003;139:161-168
  2. Doumas M, Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens. 2006;8: 269–274
  3. Douma S, Doumas M, Tsakiris A, Zamboulis C. Male and female sexual dysfunction: Is hypertension an innocent bystander or a major contributor? Rev Bras Hypertens. 2007;14: 139–147
  4. Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A et al. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl. 2006;27: 469–4775.
  5. Doumas M, Tsiodras S, Tsakiris A, Douma S, Chounta A, Papadopoulos A et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24: 2387–2392
  6. Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010; 7: 445–475
  7. Chew KK, Finn J, Stuckey B, Gibson N, Sanfilippo F, Bremner A, et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med. 2010; 7: 192–202 Jin LM. Angiotensin II signaling and its implication in erectile dysfunction. J Sex Med. 2009; 6: 302–310
  8. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, et al. Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology. 2001; 58: 805–810
  9. Yang R, Yang B, Wen Y, Fang F, Cui S, Lin G, et al. Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. J Sex Med. 2009; 6: 696–707 Comiter CV1, Sullivan MP, Yalla SV, Kifor I. Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines. Int J Impot Res. 1997; 9: 135–140 Ertemi H1, Mumtaz FH, Howie AJ, Mikhailidis DP, Thompson CS. Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: modulation of nitric oxide mediated relaxation. J Urol. 2011; 185: 2414–2420
  10. Saenz de Tejada I, Carson MP, de las Morenas A, Goldstein I, Traish AM. Endothelin: localization, synthesis, activit